Physician profile
Bassem Chaar
NPI 1497783179
$3,704.56
in general payments reported to CMS, 2019-2025
44 companies · $954 in 2025
The $954 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $456 · 2020: $213 · 2021: $182 · 2022: $468 · 2023: $535 · 2024: $897 · 2025: $954.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,286 · Education: $99.95.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,286.45 |
| Education | $99.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $841.60 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $387.35 | 2019-2024 | Keytruda, Lynparza |
| Abbvie INC. | $349.21 | 2023-2025 | Venclexta |
| Pfizer INC. | $259.79 | 2019-2024 | |
| E.R. Squibb & Sons, L.L.C. | $232.03 | 2019-2025 | Opdivo, Opdualag |
| Global Blood Therapeutics, INC. | $125.36 | 2020-2022 | |
| Sobi, INC | $119.06 | 2024-2025 | |
| Agios Pharmaceuticals, INC. | $110.78 | 2024-2025 | Pyrukynd |
| Alexion Pharmaceuticals, INC. | $101.00 | 2024 | |
| Gilead Sciences, INC. | $97.29 | 2021-2025 | Trodelvy |
| Glaxosmithkline, LLC. | $85.74 | 2025 | Jemperli, Zejula |
| Celgene Corporation | $63.00 | 2022-2025 | Reblozyl, Pomalyst |
| Genentech USA, INC. | $55.49 | 2019-2022 | |
| Myriad Genetic Laboratories, INC. | $53.78 | 2022 | |
| Amneal Pharmaceuticals LLC | $53.36 | 2024-2025 | Alymsys, Avastin |
Show all 44 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bassem Chaar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.